Search results
Can multiple myeloma be cured? Treatments and outlook
Medical News Today· 6 days agoConsolidation: This is only if a person is to receive a stem cell transplant. Maintenance: This...
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
Zacks via Yahoo Finance· 6 days agoTotal revenues increased 21% year over year to $195.9 million in the first quarter. The top line was...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme...
Is Johnson & Johnson Stock A Better Pick Over Merck?
Forbes· 16 hours agoAlthough Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2x for J&J, we think that this valuation gap will likely narrow over...
Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 7 days agoPositive Points Halozyme Therapeutics Inc (NASDAQ:HALO) reported a 15th consecutive quarter of over 15% year-over-year royalty growth, driven by products like Darzalex and ...
The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
Zacks via Yahoo Finance· 6 days agoNevertheless, J&J’s Innovative Medicine unit is performing at above-market levels. Its growth is...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 5 days agoThe company is known for its Enhanze technology, which helps deliver drugs under the skin via a...
JJ- A Healthy Dose of Income and Growth
MoneyShow via Yahoo Finance· 4 days agoJohnson & Johnson (JNJ)— founded in 1886 — is a diversified healthcare company and a leader in the area of innovative medicine and medical devices, explains Ben Reynolds, income investor and editor of Sure Dividend.
Benjamin F. Edwards & Company Inc. Purchases New Position in Genmab A/S (NASDAQ:GMAB)
ETF DAILY NEWS· 4 days agoBenjamin F. Edwards & Company Inc. acquired a new position in shares of Genmab A/S (NASDAQ:GMAB – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor acquired ...
